Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDC-0349 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GDC-0349 | DRUG | Oral escalating dose |
Inclusion Criteria: * Histologically documented, locally advanced or metastatic solid malignancy or NHL without leukemic phase that has progressed or failed to respond to at least one prior regimen and/or are not candidates for regimens known to provide clinical benefit * Evaluable or measurable di...
GDC-0349 is an investigational small molecule being studied for the treatment of Non-Hodgkin's Lymphoma and solid tumors. It is in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being evaluated for safety and tolerability in patients.
GDC-0349 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational oncology drug, which is currently in Phase 1 development for Non-Hodgkin's Lymphoma and solid tumors.
GDC-0349 is in Phase 1 clinical development. It is an investigational drug, meaning it is not yet approved by the FDA or other regulatory agencies. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing for Non-Hodgkin's Lymphoma and solid tumors.
GDC-0349 has one completed clinical trial, registered as NCT01356173. This Phase 1 study evaluated the safety and tolerability of GDC-0349 in patients with locally advanced or metastatic solid tumors or Non-Hodgkin's Lymphoma. The trial enrolled 10 participants and was conducted in the United States and Canada.
GDC-0349 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is being developed by Roche Holding AG and is currently in Phase 1 clinical trials for Non-Hodgkin's Lymphoma and solid tumors.